Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U2SURP pseudogene 1 (U2SURPP1) is categorized as a pseudogene, meaning it is a genomic DNA sequence similar to a normal gene but nonfunctional; it does not code for an active protein. While the functional gene U2SURP encodes a protein involved in RNA binding and RNA processing, U2SURPP1 itself does not produce a functional transcript or protein, and there is no evidence linking it to biological function, disease roles, or drug targeting[3]. It is listed in genomic databases for annotation purposes only.\n\nImportant context:\n- U2SURPP1 should not be confused with U2SURP (U2 snRNP associated SURP domain containing), which is a functional gene involved in RNA splicing and is associated with cancer biology[1][2][6]. However, U2SURPP1 does not share these properties or therapeutic potential. \n- There are no known drugs or biomarkers associated with U2SURPP1, nor is there any rationale for targeting it therapeutically.\n\nSummary: \nU2SURP pseudogene 1 is a nonfunctional pseudogene without known protein expression, molecular function, or role as a drug target. It is not suitable as a therapeutic target and should not be mistaken for its functional counterpart, U2SURP[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U2SURP pseudogene 1 (U2SURPP1).